Margins held; US organic slowdown sets the FY27 challenge
Reported PAT surged 25.2%, driven by operating leverage, but the critical question is buried in the granular story: US organic growth decelerated to 8.1% while guidance assumes double-digit expansion. Lannett integration and biosimilar ramp must offset this slowdown.
₹9,150 Cr
+16.3% YoY
₹1,032 Cr
+25.2% YoY
21.0%
excl. ₹43 Cr one-time
8.1% YoY
vs prior double-digit
Revenue grew 16.3% to ₹9,150 crore, but PAT surged 25.2% to ₹1,032 crore. The gap reflects genuine operating leverage: gross margin expanded 160 bps to 60.4%, and operational efficiency improved as the business scaled. After excluding a ₹43 crore one-time lease derecognition charge, EBITDA stood at ₹1,924 crore (21% margin), sustaining the prior guidance floor. This is clean, organic delivery. But the granular story is harder.
The central tension: US organic slowdown vs. double-digit guidance
US revenue reached ₹3,770 crore (+8.1% YoY, $399M), a marked deceleration from the prior 'double-digit expansion' narrative. This matters: the US segment is the largest, representing 41% of consolidated revenue. Management framed this as 'resilience' (10 launches, 10 approvals in Q1), but the momentum is plainly slowing. Yet the company maintained 'double-digit' revenue growth guidance for FY27. The gap is the quarter's real story. Lannett — the $247M acquisition closed June 29 — contributes ~$60M per quarter starting Q2 and is essential to bridge this gap. But Lannett is currently at 40% utilization, with ramp targets undisclosed and EBITDA margin blend withheld, suggesting integration complexity or competitive sensitivity.
Claims on the call: what holds up
Consolidated revenues grew 16% YoY to ₹9,150 Cr
Delivered ₹9,150.4 Cr, 16.3% YoY
Supported
EBITDA margins sustained north of 21%
₹1,924 Cr EBITDA = 21% margin after ₹43 Cr one-time charge
Supported
US growth 8.1% YoY; double-digit revenue growth FY27 guidance
Q1 US delivered 8.1%; overall guidance 'double-digit' maintained, implying Lannett uplift essential
Overstated tension
Europe 11% YoY constant currency growth
Delivered €267M at 11% CC; tracking to double-digit full year
Supported
Growth markets 38% YoY to ₹1,063 Cr
Delivered
Supported
PAT ₹1,032 Cr reflecting operating leverage
Delivered; 25.2% YoY growth vs 16.3% revenue growth confirms margin expansion
Supported
Lannett acquisition strengthens US platform with SGA synergies already realized
Closed June 29, 2026; 40% utilization, specific synergy impact and margin blend unquantified
Partial
China OSD facility production doubled over past 12 months
From ~500M tablets (FY26) to 1B+ Q1; supply now to Europe & US
Supported
What changed on this call
Lannett acquisition closed. June 29, 2026 post-FTC clearance. Adds US manufacturing footprint (350M+ capacity), controlled substance access, respiratory inhalers (Advair launching Aug 2026), and government program opportunity. Currently at 40% utilization with a 12-month strategic ramp plan. SGA synergies (~₹30–40M) already realized; procurement benefits and capacity uplift expected within 9 months. Margin convergence timeline deferred.
Biosimilar regulatory acceleration. 4 approvals now in hand (EU/UK/Canada wave-one). 2–3 US filings imminent this year. Brazil ANVISA GMP certification secured; LATAM oncology biosimilar commercialization underway. Regulatory pathway de-risked but pre-revenue (first material filings expected 2026–27, not this year).
China OSD facility production doubled YoY. From ~500M tablets (FY26) to 1B+ Q1. Supply now exported to Europe and US. Target >2B tablets by end-2027/mid-FY28. Strategic inflection point for manufacturing footprint and margin contribution.
US organic growth decelerated. Q1 FY27: 8.1% YoY (vs prior double-digit narrative). Base business resilience confirmed (10 launches, 10 approvals), but momentum is slowing. Lannett integration now essential to hit full-year double-digit guidance.
Europe EBITDA margin milestone achieved. Reached 20%+ (from single-digit 3–4 years ago). Double-digit revenue growth trajectory confirmed for full year. Cost reduction and mix improvement execution validated.
The bull-bear ledger
Consolidated growth 16.3% YoY across all geographies; all segments contributing
Margins sustained at 21% EBITDA, excl. immaterial one-time charge
Gross margin expanded 160 bps to 60.4% — genuine mix and operational leverage
Biosimilar pipeline on track: 4 approvals in hand, 2–3 US filings imminent this year, 7–8 products EU/UK/Canada by 2028–29
Europe confirmed 20%+ EBITDA, double-digit growth full year
China capacity doubled; supply to US/Europe live; >2B target by EOY/mid-FY28
US organic growth slowed to 8.1% YoY vs prior double-digit narrative; largest segment decelerating
Lannett at 40% utilization; ramp target and EBITDA margin blend withheld despite repeated analyst questions
Biosimilar and CDMO revenues pre-2026–27; TheraNym Unit 1 revenue 2028+, Unit 2 2031+; long payback window
CDMO capex concentrated; customer concentration risk (MSD anchor); validation batches 2027, ramp 2031+
Management deflected on Lannett near-term specifics (quarterly run-rate, margin assumptions) as 'confidential'
Risks, ranked by how much they should concern a holder
US organic growth deceleration and Lannett integration execution
MediumLargest segment (41% of revenue) grew only 8.1% YoY. Lannett at 40% utilization; ramp targets undisclosed. If integration stalls or margin blend is lower than Aurobindo's current ~23%, double-digit FY27 guidance will be at risk.
Lannett EBITDA margin and quarterly run-rate unquantified
MediumManagement repeatedly declined to specify Lannett EBITDA % or Q2 quarterly run-rate target despite analyst pressure (Neha Manpuria, Shyam Srinivasan). Unresolved or competitive sensitivity suggests integration complexity. Margin dilution risk if ramp slower than assumed.
Biosimilar regulatory and commercialization timeline
Medium2–3 US filings imminent but approval timelines and commercial ramp uncertain. Europe commercialization only 2 quarters in; tender-based model has natural lags. No material revenue before 2026–27. FDA/EMA draft guideline changes could alter filing timeline.
CDMO capex concentration and long payback
MediumTheraNym Unit 1 and Unit 2 represent significant capex concentration with validation 2027, revenue 2028/2031+, full ramp 2032+. Payback 6+ years out, subject to product filing and customer launch delays. Customer concentration risk (MSD anchor).
Geopolitical and macro headwinds
LowManagement cited Middle East geopolitical situation as swing factor for quarterly run-rate confidence. Europe antibiotic seasonality and currency volatility present. Diversified geographic footprint (US/Europe/growth markets/India) and backward integration mitigate.
How the street is positioned
The stock popped 3.32% by day 5 post-announcement (Aug 5), recovering from a day-1 dip of -1.52%. The initial sell-off suggests some caution on the forward guidance; the day-5 recovery reflects conviction on long-term strategy. Current price ₹1,663.4 trades above all key averages (SMA20 ₹1,587, SMA50 ₹1,544, SMA200 ₹1,335) and sits just 1.11% below the all-time high of ₹1,682. RSI stands at 72.8 — overbought territory — leaving limited room for upside surprise. The 52-week range (₹1,081–₹1,682) shows a 53.82% move off the low, a substantial rally that has already priced in much of the upside narrative.
Ownership flows tell a story of measured optimism. FII ownership rose 114 basis points QoQ to 16.38%, indicating foreign institutional appetite for the Aurobindo growth and margin story. However, DII trimmed 77 basis points to 25.10% — a modest but meaningful sign of domestic caution. The FII addition is meaningful but not overwhelming; the DII trim suggests some domestic investors are taking profits at elevated valuations.
1 · Q2 US organic growth rate and Advair launch trajectory
Advair (Lannett's flagship respiratory product) launches Aug 2026. Q2 results will reveal whether US organic growth stabilizes or continues decelerating. Does Advair + other Lannett products offset the base business slowdown? Management must quantify Q2 quarterly revenue run-rate and confirm utilization ramp timeline.
2 · Biosimilar US filing momentum and EMA approvals
2–3 US biosimilar filings imminent this year. EMA filings on track (Denosumab, Omalizumab Q3). Regulatory milestones will de-risk the commercialization timeline. Any FDA draft guideline changes or approval delays will reset the 2026–27 revenue entry point.
3 · TheraNym Unit 1 qualification and customer filing progress (Nov 2026)
Unit 1 was commissioned June 2026; validation batches expected 2027. Unit 1 revenue is pegged to begin 2028 (stockpiling dependent). Nov 2026 qualification activities begin per management timeline. Delays here will cascade Unit 2 start dates (currently Oct 2026 clearance dependent, 2031 revenue).
4 · Europe H2 new launch traction and double-digit confirmation
Europe Q1 delivered 11% CC growth; full-year double-digit guidance is maintained. Q2 and H2 launches are expected to sustain momentum. Monitor whether double-digit growth and 20%+ EBITDA margins hold as the year progresses.
5 · China OSD capacity ramp and >2B tablet target (EOY/mid-FY28)
China production at 1B+ Q1 (doubled YoY). Target >2B by EOY/mid-FY28. Monitor quarterly production data and export volumes to Europe/US. Any shortfall here impacts the margin uplift narrative for FY28+
Aurobindo delivered a strong quarter in absolute terms — 16.3% consolidated revenue growth, 25.2% PAT growth, and margin sustainability at 21% EBITDA. But the quarter masks a harder question that will define FY27: can Lannett integration and biosimilar ramp offset 8.1% US organic growth fast enough to hit double-digit guidance? The largest segment is decelerating, yet the company is maintaining 'double-digit' full-year guidance — a gap that requires near-perfect execution on Lannett utilization ramp and Advair launch success.
Management's deflection on Lannett near-term specifics (utilization ramp %, quarterly run-rate, EBITDA margin blend) during the Q&A is a yellow flag. Analysts pushed hard on these points (Neha Manpuria asked for ramp target %; Shyam Srinivasan asked for quarterly EBITDA margin), and management punted to 'confidential strategic plan' and 'offline support,' suggesting either unresolved integration complexity or sensitivity on margin assumptions. The street is priced for success (RSI 72.8, near ATH, 53.82% off the 52-week low); there is limited margin for error.
The honest read is steady execution of existing long-term strategy, not a step-change. The quarter was good, guidance was maintained not upgraded, and the path to FY27 double-digit growth is clear in broad strokes (Lannett incremental, Europe double-digit, biosimilar base contribution) but vague on near-term mechanics. Hold for strategy confirmation. The single number to track from here is Q2 US organic growth — confirm or refute the double-digit narrative.
Margin pivot and US consolidation: Aurobindo targets 21% EBITDA in FY27
With Lannett freshly closed and biosimilar capacity ramping, Q1 FY27 is the first window into Aurobindo's margin recovery story. The Street looks for steady execution on the ₹2B US sales target, while the ANVISA-cleared biosimilar facility sets up a high-margin inflection.
The numbers that matter
For Aurobindo, the story is margin recovery and US consolidation. FY27 guidance anchors at 21% EBITDA margin—a material step-up from recent run-rates—backed by Lannett cost synergies, operational leverage on higher volumes, and biosimilar commercialization. Q1 is the proof point: can the company stack acquisitions, facility upgrades, and regulatory approvals while moving the margin needle?
~₹8,200–8,500 Cr
Continuation of FY26 growth trajectory (₹33,653 Cr full year) plus Lannett full-month contribution (June only); India formulations expected in double-digit growth
~20–21%
On-plan move toward FY27 target of 21%; Lannett synergies to flow through sequentially; biosimilar facility ramp absorbs some upfront costs
Lannett momentum
Lannett contributed from June 30; full integration story plays out in H2. Combined entity targeting ₹2B US sales; acquisition was FTC-approved on expectation of EPS accretion
TheraNym Unit 1 on track
60 kL mammalian cell culture facility commissioning on schedule for end-2026; first commercial supplies to EU expected Q3/Q4 FY26 (Denosumab, Omalizumab in filing); gross margins pegged 65–70% post-commercialization
What a strong vs weak quarter looks like
Strong: Revenue meets ~₹8,200+ Cr run-rate with India formulations in double digits; EBITDA margin reaches low-20s% band, signaling Lannett synergies are materializing; management reaffirms 21% margin guidance for FY27 and gives visibility on biosimilar commercialization timeline. Weak: Revenue misses on US softness or integration friction; EBITDA margin falls below 19%, suggesting higher-than-expected integration costs or mix headwinds; any regulatory or facility delays push biosimilar timelines beyond Q3/Q4 FY26.
Is Aurobindo tracking?
Yes, on trajectory. FY26 delivered ₹33,653 Cr revenue (+6% YoY), and management has given clear FY27 guidance: 21% EBITDA margin, India formulations double-digit growth, and biosimilar facility on schedule. The Lannett deal (₹17.5 Cr in USD terms / ₹145 Cr approx) is strategic, not a capital drain—FTC approval hinged on immediate EPS accretion and synergy capture. What matters now is execution clarity: can the company absorb a large acquisition, navigate two FDA OAI classifications, and advance biosimilar commercialization in parallel? Q1 should signal parity or progress.
Since last quarter: acquisitions, approvals, and regulatory flags
Jun 30
Lannett acquisition completed
Full consolidation in Q1; cost synergies to flow Q2 onward; adds ~1.3B doses annual capacity
Jun 25
FDA inspection completed (Auroactive API facility)
Routine inspection concluded; no adverse classification reported
Jun 19
Eugia Pharma Specialities Unit-3: OAI classification
Official Action Indicated; formulation facility under regulatory focus; delay risk on product launches
Jun 12
Eugia Pharma Specialities Unit-1: OAI classification
Same facility, separate unit; two OAI flags signal multiple observation areas; remediation timeline key
Jun 04
Tofacitinib (Xeljanz generic) final FDA approval
Rheumatology launch; solid addition to specialty portfolio
Jun 03
TheraNym (biosimilar CMO) facility inaugurated
60 kL integrated mammalian cell culture live; on-plan for end-2026 commissioning
May 24
Subsidiary A1 Biochem CRO: 80% stake acquired for USD 17M
Contract research services expansion; niche capability add-on
May 21
ANVISA approval: CuraTeQ Biologics biosimilar facility (Brazil)
Regulatory clearance for high-margin biosimilar manufacturing; geographic diversification
Jul 02
Domestic business transfer to subsidiary (Auropharm Limited)
Organizational restructuring; improves tax/corporate efficiency
Jul 10
New subsidiary in Indonesia (PT Auro Pharm Indonesia)
Emerging-market footprint expansion; strategic positioning
Jul 21
MSD HIV drug licensing deal (alimatravir, royalty-free)
129 LMICs covered; non-core but strong ESG signaling; minimal revenue impact near-term
Jul 23
AGM scheduled for August 27, 2026
Annual shareholder meeting; standard governance; no extraordinary items expected
Key risks and watch items
1 · Eugia Pharma OAI remediation timeline
Two OAI classifications at Eugia units are not routine. Management guidance on remediation steps, inspection timelines, and product launch delays will be critical. Any widening of OAI flags or regulatory setbacks could cascade into US approvals and timelines.
2 · Lannett integration pace and synergy realization
Q1 saw only June contribution. The real test is H2 integration: SG&A reduction, manufacturing footprint optimization, and product portfolio rationalization. Management should detail Phase 1 milestones and cost targets for FY27.
3 · Biosimilar commercialization and gross margin validation
TheraNym is on schedule, but no commercial revenue yet. Management commentary on first customer contracts, EU filing status for Denosumab/Omalizumab, and confidence in the 65–70% gross-margin assumption is essential. Any delays push ROI out and reduce FY27 uplift.
4 · EBITDA margin bridge to 21%
Q1 EBITDA margin should inch toward 20%+. Investors need visibility into which levers drive it: Lannett synergies, leverage on volume, biosimilar facility absorption, or mix shift? A miss here signals execution risk on the full-year 21% target.
5 · India formulations growth sustainability
Guidance calls for double-digit growth. Q1 should confirm pricing held and volumes accelerated. Any miss on the domestic side would pressure the overall growth narrative, especially if US integration also sags.
Aurobindo sits at a inflection: acquisitions (Lannett, A1 Biochem), facility upgrades (TheraNym, ANVISA), regulatory progress (Tofacitinib, HIV licensing), and a clear margin target (21% EBITDA in FY27) all point to a multi-year growth arc. But Q1 FY27 is a crowded print. The market has priced in much of the Lannett upside already (+3% bounce on deal close in June); the stock is near ATH and consensus is decidedly bullish. Execution risk is real: two OAI flags, integration friction, and biosimilar timing all pose downside.
On result day, watch for three things: (1) EBITDA margin trajectory—does it credibly move toward 21%? (2) Lannett integration—is Phase 1 on track and are synergies materializing? (3) Biosimilar commercialization—do timelines hold, and is the margin story credible? A clean print with clear FY27 guidance reaffirmation could re-rate the stock. A miss on margin or a delay in any of the three legs could see the stock test support near ₹1,500.
Margins held; Lannett integration begins, biosimilars track
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Met revenue and margin guidance; confirmed biosimilar roadmap on track. Deflected on Lannett near-term specifics (utilization target, EBITDA % not disclosed).
Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong Q1 delivery: 16% revenue growth, 25% PAT growth, margins sustained at 21%. Lannett acquisition closed, biosimilar pipeline progressing (4 EU approvals, 2-3 US filings imminent), TheraNym on track for 2028 revenue. Key risk: US organic growth slowed to 8.1% vs prior double-digit narrative; Lannett EBITDA margin blend unquantified; biosimilar/CDMO revenue deferred 2028+. Lannett integration success and macro (geopolitical) will swing FY27 trajectory.
₹9150.4 Cr
Revenue · +16.3% YoY₹1032 Cr
Reported PAT · +25.2% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Consolidated revenues grew 16% YoY to ₹9,150 Cr
METDelivered ₹9,150.4 Cr, 16.3% YoY growth corroborates claim
EBITDA margins sustained north of 21%
METOperating EBITDA ₹1,924 Cr (21% margin) after ₹43 Cr one-time lease loss; excl. one-time, margin ~21.4%
US growth 8.1% YoY to ₹3,770 Cr; double-digit revenue growth FY27
OVERSTATEDDelivered as stated; US organic only 8.1% (not double-digit) yet overall guidance 'double-digit' maintained, implying Lannett uplift needed
Europe 11% YoY constant currency growth (€267M)
METDelivered; tracking to double-digit full year
Growth markets 38% YoY to ₹1,063 Cr
METDelivered
PAT ₹1,032 Cr reflecting operating leverage
METDelivered exactly; 25.2% YoY growth outpaced revenue 16.3% due to margin expansion and mix
Lannett acquisition strengthens US platform with SGA synergies already realized
PartialClosed June 29, 2026; 40% current utilization, specific synergy impact and margin blend unquantified
China OSD facility production doubled over past 12 months
METDelivered; from ~500M tablets FY26 to 1B+ Q1 FY27, supply now to Europe & US
Earnings quality
What changed since the last call
Lannett acquisition closed
NewJune 29, 2026 post-FTC approval. Adds US platform scale, controlled substance access, respiratory portfolio, government program opportunity. SGA synergies quantified offline (~₹30-40M estimated). Near-term margin impact and utilization ramp target deferred.
Biosimilar approvals and filing momentum
Upgrade4 approvals now secured (EU/UK/Canada wave-one). 2-3 US filings imminent this year. Brazil ANVISA GMP certification and LATAM oncology biosimilar commercialization underway. Regulatory pathway accelerating.
China production doubled YoY
UpgradeFrom ~500M tablets (FY26) to 1B+ Q1. Export supply to Europe and US commencing now. Target >2B tablets by EOY/mid-FY28. Strategic investment inflection to manufacturing footprint.
US organic growth deceleration
DowngradeQ1 FY27: 8.1% YoY. Prior narrative emphasized 'double-digit' expansion. Base business resilience confirmed, but momentum slowing; Lannett integration newly material to hitting full-year targets.
Europe EBITDA margin milestone achieved
UpgradeReached 20%+ (from single-digit 3-4 years ago per Subramanian). Now tracking double-digit revenue growth full year. Cost reduction and mix improvement execution validated.
R&D spend guidance lowered
NeutralFY27 expect ₹1,450-1,500 Cr (vs ₹1,600+ prior). Phase 3 clinical studies completing; transition to filing/commercialization phase. Supports margin sustainability.
The Q&A
Analysts pushed hard on Lannett near-term impact (Neha: utilization target %, Shyam: quarterly EBITDA %), Lannett margin assumptions (Abdul, Shyam), and US organic slowdown narrative (implicit tension). Management held line on long-term roadmap but deflected on specific near-term financials, framing as 'confidential strategic plan' with 9-month + benefit timeline.
Growth markets growth drivers — Tausif Shaikh, unnamed firm
PartialAll growth markets contributing in line; no single outlier. New market entry (Indonesia, China, Canada) scaling normally. Lannett Advair launching Aug 2026; rest of pipeline confidential; staggered approach.
Controlled substance quota constraints — Damayanti Kerai, unnamed firm
AnsweredControlled substance quota-limited (10,000 kg US total, allocated across suppliers). Lannett ramped recently; limited upside unless quota expands or competitor defaults. PEN-G external supplies ongoing; PLI payment Sep/Mar per government policy.
Lannett capacity ramp timeline — Neha Manpuria, unnamed firm
Partial40% utilization now. 12-month strategic plan in place (target % not disclosed). SGA synergies realized, procurement benefits + capacity uplift within 9 months. Margin catch-up medium-term (no specific year).
Biosimilar US filing status — Bino, unnamed firm
AnsweredUS filing imminent this year (one quarter variance). Brazil ANVISA GMP secured. EU filings on track (Denosumab, Omalizumab Q3). TheraNym Unit 1: 2028 onwards (stockpiling dependent), Unit 2: 2031 onwards. Combined $150-200M by 2032 at 35-50% EBITDA.
CRO/A1 Biochem integration — Shrikant Akolkar, unnamed firm
AnsweredA1 Biochem ₹100Cr revenue (2015 founding, 800+ projects, 50+ customers); CRDMO opportunity leveraging API footprint; 5-year greenfield build now 5-year head start. Closing next 1-2 months. China: doubled to 1B+ Q1, ramping to 2B+ by EOY/mid-FY28. Canada: captive supply strategy like Europe backward integration.
Eugia injectable trajectory & margins — Abdul Kader, unnamed firm
PartialEugia: steady but single-digit growth (unit-3 remediation delays); expect ~500M+ FY27 revenue. China last year ₹7Cr EBITDA loss, this year expected positive. Lannett margin detail offered offline post-call.
Lannett quarterly run-rate — Shyam Srinivasan, unnamed firm
PartialNet sales $60M quarterly without other products realistic. EBITDA will be 'much higher' (specific % declined). 2200 Cr quarterly target subject to geopolitical Middle East resolution.
R&D expense guidance — Kunal Dhamesha, unnamed firm
AnsweredPhase 3 clinical studies completed (35-36% of Aurobindo R&D in biosimilars, 7 wave-one programs mostly done). FY27 expect ₹1,450-1,500 Cr (down due to phase transition). Biosimilar R&D declining; filing/implementation phase.
US reshoring mandate readiness — Tarang Agrawal, unnamed firm
AnsweredLannett (350M+ capacity readily) + Aurolife unit + standby facility can meet demand. Reshoring = level playing field (all competitors same costs). Lannett acquisition leapfrogged 5-7 years vs greenfield build.
Biosimilar next-wave strategy — Tarang Agrawal, unnamed firm
AnsweredNext-wave actively in development. BP58 is Trastuzumab subcutaneous formulation (device differentiation, regulatory shift in EU allowing Phase 3 waivers). Positioning for device combos and post-2032 patent cliff. No wait-watch.
CDMO revenue sizing — Jigar Valia, unnamed firm
AnsweredUnit 1: 2028 onwards. Unit 2: 2031 onwards. Combined 2032: $150-200M revenue at 35-50% EBITDA margins. Product mix and customer filing timelines drive specifics.
Quarterly run-rate target — Jigar Valia, unnamed firm
PartialObjective and target are ₹2200 Cr quarterly. Dependent on geopolitical situation Middle East resolution.
Guidance
FY27 double-digit revenue growth
HighQ1 paced at 16.3% YoY. Lannett incremental (new from Q2), Europe double-digit, growth markets 38% expected to sustain trajectory.
US aspiration $2B in near term
MediumCurrent base ~$1.6B annualized (Q1 $399M × 4). Lannett adds ~$60M/Q = $1.84B+. Additional upside from respiratory portfolio and controlled substance quota expansion needed to reach $2B; timing uncertain.
Europe double-digit full year FY27
HighQ1 11% constant currency; new launches and market share gains expected Q2+ to sustain/accelerate.
Biosimilars 7-8 products EU/UK/Canada by 2028-29
High4 approvals in hand, 2-3 filings imminent this year. Regulatory pathway clear and on track per Dr. Makkapati.
EBITDA margins north of 21% FY27
HighQ1 achieved 21% (excl. ₹43Cr one-time). Management confident on sustained/progressive improvement from Lannett synergies, China positive pivot, Europe 20%+ all accretive.
Absolute EBITDA exceeding ₹8,000 Cr FY27
MediumQ1 ₹1,924Cr annualizes to ~₹7,700Cr. Target >₹8,000Cr requires stronger H2 or Lannett ramp acceleration. Achievable but tight vs guidance.
Europe EBITDA sustains 20%+ margins
HighAchieved Q1. Cost reduction programs and mix improvement support continuation per Muralidharan.
Lannett EBITDA margin catch to Aurobindo levels medium-term
MediumSpecific timeline/margin target undisclosed. SGA synergies + procurement benefits + capacity uplift expected within 9 months. Full convergence vague.
CapEx focused on TheraNym Biologics Units 1 & 2
HighNet CapEx Q1 $78M. Unit 1 commissioned June 2026; Unit 2 construction begins Oct 2026 (if clearances secured), commissioned end 2029.
A1 Biochem integration and 3-5x revenue growth over 3-5 years
MediumClosing next 1-2 months. Integration capex TBD to support scaling from ₹100Cr current base.
China facility capacity ramp to 2B+ tablets
HighProduction doubled to 1B+ Q1; capex ongoing to exceed 2B by EOY/mid-FY28.
Risks the call surfaced
US market deceleration
MediumUS organic growth slowed to 8.1% YoY (vs prior double-digit narrative). Generic pricing deflation and commodity-like competition in base business. Lannett integration at 40% utilization critical to offset, but ramp timeline vague.
Biosimilar regulatory & commercialization
Medium2-3 US biosimilar filings imminent but approval timelines and commercial ramp uncertain. Europe commercialization only 2 quarters in; tender-based sales have natural lag. No material revenue visibility before 2026-27. Regulatory risk on FTC/FDA for US filings.
Lannett margin convergence
MediumLannett current utilization 40% with specific ramp target undisclosed. EBITDA margin blend with Aurobindo portfolio unclear (Aurobindo currently higher-margin). Risk of near-term dilution if synergies don't materialize or utilization stalls.
CDMO capex and payback extension
MediumTheraNym Units 1 & 2 represent significant capex with validation batches 2027, revenue start 2028/2031, full ramp 2032. Customer concentration risk (MSD anchor). Payback 6+ years out, subject to product filing/launch delays.
Geopolitical and macro headwinds
LowManagement flagged Middle East geopolitical situation as swing factor for quarterly run-rate confidence. Europe antibiotic seasonality (Q1 weak flu season cited). Currency headwinds (Euro volatility, Indian Rupee strength).
Management
Score 7/10. Clear, structured, and specific on long-term strategy (biosimilar wave-one roadmap, TheraNym milestones, geographic expansion playbook). Transparent on constraints (controlled substance quotas, tender-based sales lags). Deflects on near-term Lannett margin impact and integration specifics (utilization target, quarterly run-rate deferred pending geopolitical clarity). Strong track record on biosimilar pipeline execution (4 approvals, 2-3 US filings imminent per timeline). Europe margin achievement (20%+ from single-digit years ago). China production doubling delivered. Lannett acquisition closed on time. R&D transition to filing phase on schedule. Weakness: US organic growth slowed (8.1% vs prior double-digit narrative); CDMO capex payback extended to 2028+.
1 · Aug 2026
Advair (Lannett) US launch; respiratory portfolio ramp critical
2 · Q2-Q3 FY27
US biosimilar filings (2-3 imminent); Xolair/Omalizumab progress EMA
3 · Nov 2026
TheraNym Unit 1 qualification activities begin per track
Lannett integration success and macro (geopolitical) will swing FY27 trajectory.
Aurobindo Q1 FY27: consolidated PAT +25% YoY to ₹1,032 Cr as margins near 21% target
PAT +25.22% YoY · revenue +16.3% · margins expanding · beat vs street
₹9,150.35 Cr
+16.3% YoY
₹1,032.03 Cr
+25.22% YoY
10.96%
+0.6pp YoY
₹17.86
Aurobindo Pharma's consolidated revenue came in at ₹9,150 Cr (+16.3% YoY, +3.4% QoQ) and PAT at ₹1,032 Cr (+25.2% YoY reported). Stripping out a ₹40.18 Cr one-off — acquisition and related costs for the Lannett Company LLC deal, booked as an exceptional item — adjusted PAT growth is closer to ~28.5% YoY, since the charge depressed rather than inflated the reported number. Standalone PAT of ₹737 Cr grew a faster 31.9% YoY; the ~6.6-point gap versus consolidated growth is explained by items that hit only the group numbers — the Lannett acquisition costs and a ₹43.26 Cr US lease-receivable derecognition loss at Aurobindo Pharma USA — so the two bases tell a similar underlying story despite the divergence.
Q1 FY-2027 vs prior quarters
Margins expanded on both counts: EBITDA (computed) of roughly ₹1,881 Cr implies a margin of ~20.6% of operating revenue, up from 19.8% in Q4 FY26 and 20.4% a year ago, while net margin rose to 11.3% from 10.3% both sequentially and annually. This tracks toward, but has not yet reached, management's stated goal from the Q4 FY26 call of sustaining and progressively improving EBITDA margin to over 21% in FY27.
The stock went into the print at ₹1,613.4, up 1.9% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.
Aurobindo Pharma projects continued growth into FY27, aiming for EBITDA margins to sustain and progressively improve to over 21%. The company anticipates robust revenue growth driven by expansion across its US business, targeting $2 billion in the near term with contributions from the Lannett acquisition and other busi
— This quarter: met
Against our pre-result preview, the print is a revenue beat: we had flagged an expected range of ₹8,200-8,500 Cr and an EBITDA margin of 20-21%; actual revenue landed well above that band while the margin printed inline within it. An independent brokerage consensus PAT figure for this specific quarter could not be confirmed via search. The broader Street stance captured in our preview was constructive but cautious — 21 of 27 covering analysts rate the stock Buy, yet the 12-month average target of ₹1,393.63 implies downside from the ₹1,580.2 pre-result price, suggesting near-term optimism was already priced in. Management's own prior guidance also pointed to US expansion toward a $2 billion sales target (aided by Lannett) and double-digit European growth; this filing discloses only a single reportable Pharmaceuticals segment with no geographic revenue break-up, so those specific targets cannot be independently verified from the numbers here, and no management press release was available to cross-check their own framing of the quarter.
W1
Q2 FY27 carries Lannett's first full-quarter contribution and integration costs — watch whether the ~20.6% EBITDA margin holds once fully consolidated
W2
EBITDA margin trajectory toward management's stated >21% FY27 target (currently ~20.6%, up from 19.8% in Q4 FY26)
W3
A1 Biochem Group acquisition (80% stake, USD 17M EV) expected to close within 90-120 days of the July 23, 2026 approval